Table 4 Factors associated with composite end point

Gender

 Male

Ref

 Female

1.09

(0.75–1.58)

Age^a, year

1.07

(1.04–1.09)

1.09

(1.05–1.13)

BMI^a, kg/m²

 < 25

Ref

Ref

 ≥ 25

1.68

(0.89–3.16)

1.42

(0.73–2.76)

Route of transmission

 Heterosexual

Ref

Ref

 MSM/bisexual

0.54

(0.35–0.82)

1.74

(0.95–3.21)

 IDU/others/unknown

0.66

(0.33–1.30)

1.06

(0.32–3.53)

Ever smoking

0.82

(0.56–1.20)

Ever alcohol drinking

0.82

(0.38–1.77)

Baseline HIV-RNA level (log₁₀ copies/mL)

1.19

(0.92–1.54)

Baseline CDC grading

 Stage A or B

Ref

 Stage C

1.03

(0.61–1.74)

Tuberculosis infection^a

 No

Ref

 Yes

1.24

(0.17–8.93)

Time since ART initiation to first viral suppression

 < 6 months

Ref

 6–12 months

0.48

(0.22–1.06)

 ≥ 12 months

1.14

(0.79–1.64)

Current CD4 counts per 100 increased

0.93

(0.85–1.02)

Current CD4/CD8

 < 0.3

3.10

(1.87–5.14)

3.02

(1.27–7.21)

 0.30–0.45

1.76

(1.13–2.75)

2.03

(1.03–3.98)

 > 0.45

Ref

Ref

Diabetes mellitus

2.27

(1.52–3.39)

3.02

(0.06–163.26)

HBs Ag status

 Negative

Ref

 Positive

0.69

(0.40–1.18)

Anti-HCV Ab status

 Negative

Ref

 Positive

1.04

(0.54–1.98)

Baseline ARV regimen

 NNRTI-based

Ref

Ref

 PI-based

1.55

(1.09–2.22)

1.09

(0.6–1.99)

cART by calendar year

 < 2007

Ref

Ref

 ≥ 2007

0.40

(0.27–0.61)

1.29

(0.7–2.36)